Atorvastatin Calcium Tablet, Film Coated
FDA Recall NDC 67877-511

Latest: Class II · Status: Ongoing · Initiated Sep 19, 2025 · 4 enforcement reports

Active & Historical Enforcement Reports

The FDA has identified 4 recorded enforcement report(s) associated with Atorvastatin Calcium (NDC 67877-511). A significant event, classified as Class II, was initiated on Sep 19, 2025 by Ascend Laboratories, Llc. The reported reason for this action was: "Failed Dissolution Specifications"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

September 2025 Class II Recall: Failed Dissolution Specifications

Recall Number
Class II Ongoing
Reason for Recall
Failed Dissolution Specifications
Initiated
Sep 19, 2025
Reported
Oct 22, 2025
Quantity
141,984 bottles

Recall Profile & Regulatory Data

Event ID
97639
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Ascend Laboratories, LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
U.S. Nationwide
Product Description
Atorvastatin Calcium Tablets USP, 10 mg, Rx Only a) 90-count bottle (NDC 67877-511-90), b). 500-count bottle (NDC 67877-511-05), c). 1000-count bottle (NDC 67877-511-10) Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054.
Batch or Lot Expiration Information
Lot# : 25141249, Exp. Feb. 2027
Lot# : 24144938, Exp. Nov. 2026
Lot# : 24144868, Exp. Nov. 2026
Lot# : 24144867, Exp. Nov. 2026
Lot# : 24144458, Exp. Sep. 2026
Lot# : 24143994, Exp. Sep. 2026
Lot# : 24142987, Exp. July 2026
Lot# : 24143316, Exp. July 2026
Affected Packages Involved in this Recall
67877-511-90Atorvastatin Calcium
67877-511-05Atorvastatin Calcium
67877-511-10Atorvastatin Calcium
67877-511-55Atorvastatin Calcium
67877-511-33Atorvastatin Calcium
67877-511-38Atorvastatin Calcium
67877-512-90Atorvastatin Calcium
67877-512-05Atorvastatin Calcium
67877-512-10Atorvastatin Calcium
67877-512-44Atorvastatin Calcium
67877-512-33Atorvastatin Calcium
67877-512-38Atorvastatin Calcium
67877-513-90Atorvastatin Calcium
67877-513-05Atorvastatin Calcium
67877-513-10Atorvastatin Calcium
67877-513-23Atorvastatin Calcium
67877-513-33Atorvastatin Calcium
67877-513-38Atorvastatin Calcium
67877-514-90Atorvastatin Calcium
67877-514-05Atorvastatin Calcium
67877-514-10Atorvastatin Calcium
67877-514-33Atorvastatin Calcium
67877-514-38Atorvastatin Calcium

September 2025 Class II Recall: Failed Dissolution Specifications

Recall Number
Class II Ongoing
Reason for Recall
Failed Dissolution Specifications
Initiated
Sep 19, 2025
Reported
Oct 22, 2025
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
97639
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Ascend Laboratories, LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
U.S. Nationwide
Product Description
Atorvastatin Calcium Tablets USP, 80 mg, Rx Only, a). 90-count(NDC 67877-514-90), b). 500-count(NDC 67877-514-05), Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054
Batch or Lot Expiration Information
Lot# : 25140249, Exp. Dec. 2026
Lot# : 25140247, Exp. Dec. 2026
Lot# : 24144999, Exp. Nov. 2026
Lot# : 24144942, Exp. Nov. 2026
Lot# : 24144845, Exp. Nov. 2026
Lot# : 24144713, Exp. Nov. 2026
Lot# : 24144652, Exp. Oct. 2026
Lot# : 24143898, Exp. Aug. 2026
Lot# : 24143412, Exp. Aug. 2026
Lot# : 24143582, Exp. Aug. 2026
Affected Packages Involved in this Recall
67877-511-90Atorvastatin Calcium
67877-511-05Atorvastatin Calcium
67877-511-10Atorvastatin Calcium
67877-511-55Atorvastatin Calcium
67877-511-33Atorvastatin Calcium
67877-511-38Atorvastatin Calcium
67877-512-90Atorvastatin Calcium
67877-512-05Atorvastatin Calcium
67877-512-10Atorvastatin Calcium
67877-512-44Atorvastatin Calcium
67877-512-33Atorvastatin Calcium
67877-512-38Atorvastatin Calcium
67877-513-90Atorvastatin Calcium
67877-513-05Atorvastatin Calcium
67877-513-10Atorvastatin Calcium
67877-513-23Atorvastatin Calcium
67877-513-33Atorvastatin Calcium
67877-513-38Atorvastatin Calcium
67877-514-90Atorvastatin Calcium
67877-514-05Atorvastatin Calcium
67877-514-10Atorvastatin Calcium
67877-514-33Atorvastatin Calcium
67877-514-38Atorvastatin Calcium

September 2025 Class II Recall: Failed Dissolution Specifications

Recall Number
Class II Ongoing
Reason for Recall
Failed Dissolution Specifications
Initiated
Sep 19, 2025
Reported
Oct 22, 2025
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
97639
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Ascend Laboratories, LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
U.S. Nationwide
Product Description
Atorvastatin Calcium Tablets USP, 40 mg, Rx Only, a). 90-count (NDC 67877-513-90), b). 500-count (NDC 67877-513-05), c). 1000-count (NDC 67877-513-10), Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054.
Batch or Lot Expiration Information
Lot# : 25140933, Exp. Feb. 2027
Lot# : 25140477, Exp. Dec. 2026
Lot# : 24144254, Exp. Oct. 2026
Lot# : 24144163, Exp. Sep. 2026
Lot# : 24143995, Exp. Sep. 2026
Affected Packages Involved in this Recall
67877-511-90Atorvastatin Calcium
67877-511-05Atorvastatin Calcium
67877-511-10Atorvastatin Calcium
67877-511-55Atorvastatin Calcium
67877-511-33Atorvastatin Calcium
67877-511-38Atorvastatin Calcium
67877-512-90Atorvastatin Calcium
67877-512-05Atorvastatin Calcium
67877-512-10Atorvastatin Calcium
67877-512-44Atorvastatin Calcium
67877-512-33Atorvastatin Calcium
67877-512-38Atorvastatin Calcium
67877-513-90Atorvastatin Calcium
67877-513-05Atorvastatin Calcium
67877-513-10Atorvastatin Calcium
67877-513-23Atorvastatin Calcium
67877-513-33Atorvastatin Calcium
67877-513-38Atorvastatin Calcium
67877-514-90Atorvastatin Calcium
67877-514-05Atorvastatin Calcium
67877-514-10Atorvastatin Calcium
67877-514-33Atorvastatin Calcium
67877-514-38Atorvastatin Calcium

September 2025 Class II Recall: Failed Dissolution Specifications

Recall Number
Class II Ongoing
Reason for Recall
Failed Dissolution Specifications
Initiated
Sep 19, 2025
Reported
Oct 22, 2025
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
97639
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Ascend Laboratories, LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
U.S. Nationwide
Product Description
Atorvastatin Calcium Tablets USP, 20 mg, Rx Only, a). 90-count(NDC 67877-512-90), b). 500-count (NDC 67877-512-05), c). 1000-count(NDC 67877-512-10),Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054.
Batch or Lot Expiration Information
Lot# : 25140150, Exp. Dec. 2026
Lot# : 25140173, Exp. Dec. 2026
Lot# : 25140172, Exp. Dec. 2026
Lot# : 24144720, Exp. Nov. 2026
Lot# : 24144798, Exp. Nov. 2026
Lot# : 24144692, Exp. Oct. 2026
Lot# : 24143755, Exp. Aug. 2026
Lot# : 24143913, Exp. Aug. 2026
Lot# : 24143754, Exp. Aug. 2026
Lot# : 24143047, Exp. June 2026
Lot# : 24142936, Exp. July 2026
Affected Packages Involved in this Recall
67877-511-90Atorvastatin Calcium
67877-511-05Atorvastatin Calcium
67877-511-10Atorvastatin Calcium
67877-511-55Atorvastatin Calcium
67877-511-33Atorvastatin Calcium
67877-511-38Atorvastatin Calcium
67877-512-90Atorvastatin Calcium
67877-512-05Atorvastatin Calcium
67877-512-10Atorvastatin Calcium
67877-512-44Atorvastatin Calcium
67877-512-33Atorvastatin Calcium
67877-512-38Atorvastatin Calcium
67877-513-90Atorvastatin Calcium
67877-513-05Atorvastatin Calcium
67877-513-10Atorvastatin Calcium
67877-513-23Atorvastatin Calcium
67877-513-33Atorvastatin Calcium
67877-513-38Atorvastatin Calcium
67877-514-90Atorvastatin Calcium
67877-514-05Atorvastatin Calcium
67877-514-10Atorvastatin Calcium
67877-514-33Atorvastatin Calcium
67877-514-38Atorvastatin Calcium

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.